Manufacturing

Articles

The US Department of Health and Human Services (HHS, Washington, DC) will distribute more than $1 billion in contracts to accelerate the development of cell-based production technologies for influenza vaccines.

HHS Awards $1 Billion in Contracts to Speed Cell-Based Vaccine Development

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

Novartis (Basel, Switzerland) has closed on its $5.4-billion acquisition of Chiron Corporation (Emeryville, CA), paving the way for the creation of a new Novartis division focusing on vaccines and diagnostics.

Novartis Creates New Vaccines Division Following Close of Chiron Deal

Reverse Genetics Avian Influenza Vaccine Approved in France

GSK Begins Clinical Trials of Two H5N1 Vaccines

Cell-culture technology and financial incentives give influenza vaccine makers a much-needed shot in the arm, but many downstream processing issues remain unaddressed. 

Process Considerations for Cell-Based Influenza Vaccines

Progress Continues in Vaccine and Antiviral Development

Chiron Withdraws Measles Vaccine

Development Begins on Mutated H5N1 Virus Vaccine

Vaccine Update: New Avian Strain, FDA Guidelines, and Clinical Funding

Novavax, Bharat Biotech Team for Pandemic Influenza Vaccine Development

GSK Gains Approval for Rotavirus Vaccine in Infants; FDA Review Extended for Merck’s Shingles Vaccine

Manufacturing, Biologic Drugs